TrialESMO open2025

Liver metastases do not predict resistance to the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab in proficient MMR metastatic colorectal cancer: a secondary analysis of the AtezoTRIBE study.

C Antoniotti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.